Download
journal.pone.0288259.pdf 2,10MB
WeightNameValue
1000 Titel
  • Co-crystallisation and humanisation of an anti-HER2 single-domain antibody as a theranostic tool
1000 Autor/in
  1. Sawmynaden, Kovilen |
  2. Wong, Nicholas |
  3. Davies, Sarah |
  4. Cowan, Richard |
  5. Brown, Richard |
  6. Tang, David |
  7. Henry, Maud |
  8. Tickle, David |
  9. Matthews, David |
  10. Carr, Mark |
  11. Bakrania, Preeti |
  12. Hoi Ting, Hong |
  13. Hall, Gareth |
1000 Erscheinungsjahr 2023
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2023-07-17
1000 Erschienen in
1000 Quellenangabe
  • 18(7):e0288259
1000 Copyrightjahr
  • 2023
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1371/journal.pone.0288259 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10351726/ |
1000 Ergänzendes Material
  • https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0288259#sec027 |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Human epidermal growth factor receptor-2 (HER2) is a well-recognised biomarker associated with 25% of breast cancers. In most cases, early detection and/or treatment correlates with an increased chance of survival. This study, has identified and characterised a highly specific anti-HER2 single-domain antibody (sdAb), NM-02, as a potential theranostic tool. Complete structural description by X-ray crystallography has revealed a non-overlapping epitope with current anti-HER2 antibodies. To reduce the immunogenicity risk, NM-02 underwent a humanisation process and retained wild type-like binding properties. To further de-risk the progression towards chemistry, manufacturing and control (CMC) we performed full developability profiling revealing favourable thermal and physical biochemical ‘drug-like’ properties. Finally, the application of the lead humanised NM-02 candidate (variant K) for HER2-specific imaging purposes was demonstrated using breast cancer HER2+/BT474 xenograft mice.
1000 Sacherschließung
lokal In vivo imaging
lokal Enzyme-linked immunoassays
lokal Breast cancer
lokal Theranostics
lokal Antibody therapy
lokal Mouse models
lokal Cancer treatment
lokal Renal cancer
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/U2F3bXluYWRlbiwgS292aWxlbg==|https://frl.publisso.de/adhoc/uri/V29uZywgTmljaG9sYXM=|https://frl.publisso.de/adhoc/uri/RGF2aWVzLCBTYXJhaA==|https://orcid.org/0000-0003-0311-9739|https://frl.publisso.de/adhoc/uri/QnJvd24sIFJpY2hhcmQ=|https://frl.publisso.de/adhoc/uri/VGFuZywgRGF2aWQ=|https://frl.publisso.de/adhoc/uri/SGVucnksIE1hdWQ=|https://frl.publisso.de/adhoc/uri/VGlja2xlLCBEYXZpZA==|https://frl.publisso.de/adhoc/uri/TWF0dGhld3MsIERhdmlk|https://frl.publisso.de/adhoc/uri/Q2FyciwgTWFyaw==|https://frl.publisso.de/adhoc/uri/QmFrcmFuaWEsIFByZWV0aQ==|https://frl.publisso.de/adhoc/uri/SG9pIFRpbmcsIEhvbmc=|https://orcid.org/0000-0001-6662-3794
1000 (Academic) Editor
1000 Label
1000 Förderer
  1. LifeArc |
  2. NanoMab |
1000 Fördernummer
  1. -
  2. -
1000 Förderprogramm
  1. -
  2. -
1000 Dateien
1000 Förderung
  1. 1000 joinedFunding-child
    1000 Förderer LifeArc |
    1000 Förderprogramm -
    1000 Fördernummer -
  2. 1000 joinedFunding-child
    1000 Förderer NanoMab |
    1000 Förderprogramm -
    1000 Fördernummer -
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6453387.rdf
1000 Erstellt am 2023-08-07T11:37:17.037+0200
1000 Erstellt von 337
1000 beschreibt frl:6453387
1000 Bearbeitet von 317
1000 Zuletzt bearbeitet 2023-08-08T08:56:53.468+0200
1000 Objekt bearb. Tue Aug 08 08:56:36 CEST 2023
1000 Vgl. frl:6453387
1000 Oai Id
  1. oai:frl.publisso.de:frl:6453387 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source